Patent Description:
AL amyloidosis involves a hematological disorder caused by clonal plasma cells that produce immunoglobulin light chains that can misfold and contribute to disease. Overproduction of misfolded light chain by plasma cells results in deposits of abnormal AL protein (amyloid) in the tissues and organs of individuals with AL amyloidosis. Clinical features of AL amyloidosis include a constellation of symptoms and organ dysfunction that can include cardiac, renal, and hepatic dysfunction, gastrointestinal involvement, neuropathies and macroglossia. The mechanisms by which amyloidogenic immunoglobulin light chains result in organ dysfunction are not well characterized, however, it is hypothesized that both amyloid deposits and prefibrillar aggregates may contribute to cytotoxic effects on organs observed in patients with AL amyloidosis. AL amyloidosis is a disease entity of its own, although AL amyloidosis can occur concurrently in a subset of patients with multiple myeloma (up to <NUM>%) or monoclonal gammopathy of unknown significance (MGUS; up to <NUM>%).

AL amyloidosis is a rare disorder with an estimated incidence of <NUM> in <NUM>,<NUM>,<NUM> people. Only <NUM> to <NUM> new cases of AL amyloidosis are reported each year in the United States. Two thirds of patients with AL amyloidosis are male and less than <NUM>% of patients are under <NUM> years of age. Both the causes and origins of AL amyloidosis remain poorly understood. The outcome of the disease for patients with AL amyloidosis can be predicted based on the Mayo four stage prognostic staging system discussed in Kumar et al. , <NUM> (<NPL>), with the outcome for Stage IV patients being quite dire.

Current treatment of patients with AL amyloidosis is aimed at reducing or eliminating the bone marrow disorder, i.e. the plasma cells that are responsible for producing the light chains, thereby limiting or halting the production of amyloid. The most aggressive treatment options include stem cell transplant and high-dose chemotherapy for those patients who can tolerate it. Other treatment regimens include combinations of drugs often used to treat hematological malignancies, such as melphalan, prednisone, dexamethasone and proteosome inhibitors such as bortezomib, in an attempt to reduce light chain production. There are no currently approved treatments for AL amyloidosis, and none that directly target potentially toxic forms of the amyloidogenic proteins. While some treatment options may ameliorate some of the morbidity associated with AL amyloidosis, few if any have been demonstrated to improve the prognosis in patients. Furthermore, Mayo Stage IV patients with AL amyloidosis represent a patient subset with a very high burden of morbidity and mortality, with no currently approved treatments, and population estimates of approximately <NUM>,<NUM> patients in the U. , and from <NUM>,<NUM> to <NUM>,<NUM> patients in the U. and the European Union combined.

Thus, there is an unmet need for therapies that improve health status, including reducing the risk of mortality or enhancing the quality of life in patients with AL amyloidosis.

The present invention relates to an antibody comprising VL CDRs according to SEQ ID NOs: <NUM>, <NUM>, and <NUM>, and VH CDRs according to SEQ ID NOs: <NUM>, <NUM>, and <NUM>, for use in methods of treating certain AL amyloidosis patients as defined in the claims.

Provided herein are methods of treating a patient having AL amyloidosis, comprising determining the Mayo Stage of the patient's AL amyloidosis, and/or the <NUM> minute walk distance (6MWD) and ejection fraction (EF) of the patient, or determining the Mayo Stage and EF of the patient, selecting the patient for treatment with an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to human kappa (κ) or lambda light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>) if the patient has Mayo Stage IV AL amyloidosis, has a 6MWD ≥ <NUM> meters and an EF > <NUM>% at baseline, has Mayo Stage IV and EF > <NUM>% at baseline, or has Mayo Stage IV, a 6MWD ≥ <NUM> meters and an EF > <NUM>% at baseline, and administering an effective dosage of the antibody. In some disclosures, the patient has Mayo Stage IV AL amyloidosis. Some such Mayo Stage IV patients have an EF ><NUM>%, and some of such patients also have a 6MWD ≥ <NUM> meters.

Also provided herein are methods of treating a patient having AL amyloidosis, comprising administering an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to κ or lambda light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>), wherein the patient has (a) Mayo Stage IV AL amyloidosis (b) a <NUM> minute walk distance (MWD) ≥ <NUM> meters and an ejection fraction (EF) > <NUM>%, (c) Mayo Stage IVC and an EF > <NUM>% or (d) Mayo Stage IV and a 6MWD ≥ <NUM> meters and an EF > <NUM>%. In some disclosures, the patient has Mayo Stage IV AL amyloidosis. In some disclosures, the patient has a 6MWD ≥ <NUM> meters and an EF > <NUM>%, and some of such patients have Mayo Stage IV AL amyloidosis. In some disclosures, the Mayo Stage IV patients have an EF > <NUM>%.

Provided herein are methods of treating a Mayo Stage IV patient with AL amyloidosis comprising administering an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to human kappa (κ) or lambda light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>). In some disclosures, the method reduces the risk of mortailtiy in the patient. In some disclosures, the method reduces the risk of all-cause mortality in the patient. In some disclosures, the method of treatment reduces the risk of cardiac mortality in the patient.

Provided herein are methods of treating a Mayo Stage IV patient with AL amyloidosis comprising administering an effective dosage of birtamimab. In some disclosures, the method reduces the risk of mortality in the patient. In some disclosures, the method reduces the risk of all-cause mortality in the patient. In some disclosures, the method of treatment reduces the risk of cardiac mortality in the patient. In some disclosures, the dosage is from about <NUM>/kg to about <NUM>/kg, and birtamimab is administered intravenously or subcutaneously at a frequency of from about weekly to about quarterly. In some disclosures, the dosage is about <NUM>/kg and birtamimab is administered intravenously every <NUM> days.

In some disclosures provided herein, antibody comprises a light chain variable region comprising three complementarity determining regions of 2A4, 7D8 or <NUM>-1F4, and a heavy chain variable region comprising three complementarity determining regions of 2A4, 7D8 or <NUM>-1F4, respectively. In some disclosures, the antibody is a humanized version of 2A4. In some disclosures the antibody is a humanized or chimeric version of <NUM>-1F4.

In some disclosures, the antibody binds to the same epitope as 2A4, 7D8 or <NUM>-1F4. In some disclosures the patient is administered an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number <NUM>) or or competes for binding to κ or lambda light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>). In some disclosures, the antibody binds to the same epitope as 2A4 or <NUM>-1F4. In some disclosures, the antibody is a humanized version of 2A4. In some disclosures, the antibody is a humanized or chimeric version of <NUM>-1F4. In some disclosures, the antibody is a humanized bispecific or multispecific version containing combinations of <NUM>-1F4, 2A4, and/or 7D8.

In some disclosures provided herein, the antibody comprises a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>, or SEQ ID NOs: <NUM>, <NUM>, and <NUM>, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>, or SEQ ID NOs: <NUM>, <NUM>, and <NUM>. In some disclosures, the light chain variable region of the antibody comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM>. In some disclosures, the heavy chain variable region of the antibody comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM>. In some disclosures, the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM> and the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM>. In some disclosures provided herein, the antibody comprises a light chain comprising the amino acid sequence set forth as SEQ ID NO:<NUM> and a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: <NUM>, <NUM> or <NUM>. In some disclosures, the antibody comprises a light chain comprising the amino acid sequence set forth as SEQ ID NO:<NUM> and a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: <NUM>. In some disclosures, the antibody is birtamimab.

In some disclosures provided herein, the patient is newly diagnosed and AL amyloidosis treatment naive. In some disclosures, the patient previously received or concomitantly receives treatment with melphalan, prednisone, dexamethasone, bortezomib, cyclophosphamide, lenalidomide, doxorubicin, doxycycline, daratumumab, autologous transplant or a combination thereof. In certain methods, the patient previously received or concomitantly receives treatment with humanized 2A4, 7D8, or <NUM>-1F4 in advance of recreiving plasma cell therapy.

Provided herein are methods comprising administering to a Mayo Stage IV patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number <NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>), thereby reducing the patient's relative risk of mortality by at least about <NUM>%.

Also provided herein are methods of treating a patient with AL amyloidosis, comprising determining that the patient has a <NUM> minute walk distance (6MWD) ≥ <NUM> meters and an ejection fraction (EF) > <NUM>%, selecting the patient for treatment with an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>), and administering an effective dosage of the antibody.

Also provided herein are methods of treating a patient with AL amyloidosis who has a demonstrated <NUM> minute walk distance (6MWD) of greater than or equal to <NUM> meters and an ejection fraction (EF) of more than <NUM>%, comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to κ light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>).

Also provided herein are methods of improving a <NUM> minute walk distance (6MWD) in a patient having AL amyloidosis, comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>). In some disclosures, the patient has Mayo Stage IV AL amyloidosis. In some disclosures, the patient has an EF > <NUM>%. In some disclosures, the Mayo Stage IV patients have an EF > <NUM>%.

Also provided herein are methods of reducing the risk of mortality in a patient with AL amyloidosis by at least <NUM>% relative to control conditions (relative risk), comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>), wherein the patient has Mayo Stage IV AL amyloidosis and/or has a demonstrated <NUM> minute walk distance (6MWD) of greater than or equal to <NUM> meters and an ejection fraction (EF) of more than <NUM>% or has Mayo Stage IV AL amyloidosis and an EF > <NUM>%. In some disclosures, the method reduces the risk of all-cause mortality in the patient. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of all-cause mortality is reduced by at least <NUM>% relative to control conditions. In some disclosures, the method reduces the risk of cardiac mortality in the patient. In some disclosures, the risk of cardiac mortality is reduced by at least about <NUM>% relative to control conditions. In some disclosures, the risk of cardiac mortality is reduced by at least about <NUM>% relative to control conditions.

In some disclosures provided herein, the patient exhibits improvement in the <NUM>-Item Short Form Survey Physical Component Score (SF-<NUM> PCS) or SF-36v2 following treatment with the antibody. In some disclosures, after nine months of treatment the change in the patient's score on the SF-<NUM> PCS or SF-36v2 is at least <NUM> points higher relative to a different patient at the same time point who has not been administered the antibody.

In some disclosures provided herein, the effective dosage of the antibody is administered from a pharmaceutical formulation comprising the antibody at a concentration within the range from about <NUM>/mL to about <NUM>/mL. In some disclosures provided herein, the effective dosage of the antibody is administered from a pharmaceutical formulation comprising, histidine buffer at a concentration within the range from about <NUM> to about <NUM>, trehalose at a concentration within the range from about <NUM> to about <NUM>, and polysorbate <NUM> at a concentration within the range from about <NUM>% to about <NUM>% by weight, and the formulation has a pH within the range from about <NUM> to about <NUM>. In some disclosures, the dosage is from about <NUM>/kg to about <NUM>/kg and the antibody is administered intravenously or subcutaneously at a frequency of from about weekly to about quarterly. In some disclosures, the antibody is present at a concentration of about <NUM>/mL. In some disclosures provided herein, the pharmaceutical formulation comprises, the histidine buffer at a concentration of about <NUM>, the trehalose at a concentration of about <NUM>, the polysorbate <NUM> at a concentration of about <NUM>/L, and the pH is about <NUM>.

In some disclosures provided herein, the dosage is administered subcutaneously without dilution from a vial containing the formulation. In some disclosures, the dosage is administered intravenously following the transfer of an amount of the formulation required for the dosage from a vial to an intravenous bag containing a liquid.

In some disclosures provided herein, the dosage is about <NUM>/kg and the antibody is administered intravenously every <NUM> days. In some disclosures provided herein, the dosage is administered intravenously (IV) at <NUM>/kg (dose not to exceed <NUM>) once every <NUM> days (± <NUM> days). In some disclosures, the duration of the treatment is at least <NUM> months. In some disclosures, the duration of the treatment is at least <NUM> months. In some disclosures, the duration is effective to achieve or maintain at least about a <NUM> point increase from baseline in SF-<NUM> PCS.

In some disclosures provided herein, the antibody is a Fab, Fab', F(ab')<NUM>, F(ab)c, Dab, nanobody or Fv.

Also provided herein is an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>) for use in a method of treating a patient with Mayo Stage IV AL amyloidosis, a patient who has at baseline a demonstrated <NUM> minute walk distance (6MWD) of greater than or equal to <NUM> meters and an ejection fraction (EF) of more than <NUM>%, a Mayo Stage IV patient who has at baseline an EF of more than <NUM>%, or a Mayo Stage IV patient who has at baseline a 6MWD of greater than or equal to <NUM> meters and an EF of more than <NUM>%. In some disclosures, the antibody is a humanized version of 2A4. Some such antibodies comprise a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>, or SEQ ID NO:<NUM>, <NUM>, and <NUM>, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>,or SEQ ID NOs:<NUM>, <NUM> and <NUM>. In some antibodies the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> of <NUM>. In some antibodies, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM>. In some antibodies the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM> and the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM> or <NUM>.

Some antibodies provided herein are formulated as a pharmaceutical formulation comprising the antibody at a concentration within the range from about <NUM>/mL to about <NUM>/mL, histidine buffer at a concentration within the range from about <NUM> to about <NUM>, trehalose at a concentration within the range from about <NUM> to about <NUM>, polysorbate <NUM> at a concentration within the range from about <NUM>% to about <NUM>% by weight, and the pharmaceutical formulation is characterized by a pH within the range from about <NUM> to about <NUM>.

Some uses of the antibody comprise a dosage from about <NUM>/kg to about <NUM>/kg and wherein the antibody is administered intravenously or subcutaneously at a frequency of from about weekly to about quarterly. For some uses, the antibody is present at a concentration of about <NUM>/mL, the histidine buffer is present at a concentration of about <NUM>, the trehalose is present at a concentration of about <NUM>, the polysorbate <NUM> is present at a concentration of about <NUM>/L, and the pH is about <NUM>.

Also provided herein are methods of identifying a patient likely to receive a health benefit from treatment with an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or 7D8 (ATCC Accession Number PTA-<NUM>), or competes for binding to kappa light chain immunoglobulin with <NUM>-1F4 (ATCC Accession Number PTA-<NUM>), comprising determining (a) whether the patient has Mayo Stage I, Stage II, Stage III or Stage IV AL amyloidosis, (b) the <NUM> minute walk distance (6MWD) of the patient, and/or (c) the ejection fraction (EF) of the patient, and selecting for treatment a patient with (i) Stage IV AL amyloidosis, (ii) a patient with a 6MWD ≥ <NUM> meters and an EF > <NUM>%, (iii) Stage IV AL amyloidosis and a 6MWD ≥ <NUM> meters and an EF > <NUM>%, or (iv) Stage IV AL amyloidosis and an EF > <NUM>%. In some disclosures, the selected patient has Mayo Stage IV AL amyloidosis. In some disclosures, the selected patient has a 6MWD ≥ <NUM> meters and an ejection fraction > <NUM>%. In some disclosures, the selected patient has Mayo Stage IV AL amyloidosis and a 6MWD ≥ <NUM> meters and an ejection fraction > <NUM>%. Some methods further comprise administering intravenously to the patient a dose in the range of about <NUM>/m2 to about <NUM>/m2 of a chimeric or humanized version of <NUM>-1F4, or a dose in the range of about <NUM>/kg to about <NUM>/kg of a humanized version of 2A4.

The disclosure provides methods of treating certain AL amyloidosis patients, namely patients with Mayo Stage IV AL amyloidosis, patients with a baseline six minute walk distance (6MWD; sometimes refered to as the six minute walk test (6MWT) distance) greater than or equal to <NUM> meters and ejection fraction (EF) greater than <NUM>%, Mayo Stage IV patients with a baseline EF greater than <NUM>%, and Mayo Stage IV patients with a baseline 6MWD greater than or equal to <NUM> meters and ejection fraction (EF) greater than <NUM>%. The methods involve administering to such patients an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with antibody 2A4 (ATCC Accession Number PTA-<NUM>) or antibody 7D8 (ATCC Accession Number PTA-<NUM>) or which competes for binding to kappa immunoglobulin light chain with antibody <NUM>-1F4 (ATCC Accession Number PTA-<NUM>). In some disclosures, the antibody is birtamimab.

The term "antibody" includes intact antibodies and antigen-binding fragments thereof. Typically, fragments compete with the intact antibody from which they were derived for specific binding to the target including separate heavy chains, light chains Fab, Fab', F(ab')<NUM>, F(ab)c, Dabs, nanobodies, and Fv. Fragments can be produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins. The term "antibody" also includes a bispecific or multispecific antibody and/or a humanized antibody. A bispecific or bifunctional or multifunctional antibody is an artificial hybrid antibody having two or more different heavy/light chain pairs and two or more different binding sites (see, e.g., <NPL>); <NPL>)).

The term "censoring" refers to a situation in which the value of a measurement or observation is only partially known. For example, if a study is conducted to measure the impact of a drug on mortality rate, survival will be assumed for the period of the study in the absence of data indicating death, such that patients who withdrew from the study are considered to be alive through the duration of the study regardless of their unknown disposition (i.e., alive or dead).

The term "ejection fraction" or "EF" refers to the measurement of how much blood the left ventricle pumps out with each contraction. An ejection fraction of <NUM> percent means that <NUM> percent of the total amount of blood in the left ventricle is pushed out with each heartbeat. Ejection fraction is used as a measure of heart failure. The EF of a normal heart is typically between <NUM>-<NUM> percent. <NUM>-<NUM> percent may be considered borderline and an EF under <NUM> percent may be evidence of heart failure or cardiomyopathy.

The term "hazard ratio" or "HR" reflects the instantaneous probability (i.e., hazard rate) of an event (death or progression) in the experimental arm as a ratio to the probability in the comparator arm. If the HR is <NUM>, there is no clear advantage for either arm. The lower the HR value, the greater the reduction in risk of death or progression for the experimental treatment arm of the study, which is calculated as <NUM>-HR. For example, an HR of <NUM> equals a <NUM>% relative reduction in event risk in comparison with the control arm of the study.

The term "humanized immunoglobulin" or "humanized antibody" refers to an immunoglobulin or antibody that includes at least one humanized immunoglobulin or antibody chain (i.e., at least one humanized light or heavy chain). The term "humanized immunoglobulin chain" or "humanized antibody chain" (i.e., a "humanized immunoglobulin light chain" or "humanized immunoglobulin heavy chain") refers to an immunoglobulin or antibody chain (i.e., a light or heavy chain, respectively) having a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) (e.g., at least one CDR, preferably two CDRs, more preferably three CDRs) substantially from a non-human immunoglobulin or antibody, and further includes constant regions (e.g., at least one constant region or portion thereof, in the case of a light chain, and preferably three constant regions in the case of a heavy chain). The term "humanized variable region" (e.g., "humanized light chain variable region" or "humanized heavy chain variable region") refers to a variable region that includes a variable framework region substantially from a human immunoglobulin or antibody and complementarity determining regions (CDRs) substantially from a non-human immunoglobulin or antibody.

The term "Mayo Stage IV patients" or "Stage IV" refers to patients with stage IV disease according to the prognostic staging system established by the Mayo Clinic (<NPL>), which incorporates both cardiac biomarkers and level of amyloidogenic light chain synthesis. Collectively, patients with stage I, stage II or stage III disease are referred to herein as "Mayo Stage I-III patients" or "Stage I-III patients". In some disclosures, a patient is identified as having Stage IV AL amyloidosis if they meet the criteria for the following three prognostic variables: troponin-T (cTnT) ≥ <NUM> ng/mL, N-terminal pro-B-type natriuretic peptide (NT-ProBNP) ≥ <NUM>,<NUM> pg/mL, and difference between involved and univolved light chain (FLC-diff or dFLC) ≥ <NUM>/dL). In certain disclosures, a patient can be confirmed as Mayo Stage IV as defined by: (<NUM>) NT-proBNP ≥ <NUM> pg/mL, (<NUM>) Troponin-T > <NUM> ng/mL, and (<NUM>) dFLC ≥ <NUM>/dL.

The term "p-value" or "p" refers to a number between <NUM> and <NUM> relating to the significance of results obtained. A small p-value indicates strong evidence against the null hypothesis (i.e., the hypothesis that there is no effect), for example ≤<NUM>, indicates statistical significance, with p ≤<NUM> being statistically highly significant (less than one in a thousand chance of being wrong).

The phrase "substantially from a human immunoglobulin or antibody" means that, when aligned to a human immunoglobulin or antibody amino sequence for comparison purposes, the region shares at least <NUM>-<NUM>%, preferably <NUM>-<NUM>%, more preferably <NUM>-<NUM>% identity (i.e., local sequence identity) with the human framework or constant region sequence, allowing, for example, for conservative substitutions, consensus sequence substitutions, germline substitutions, backmutations, and the like. The introduction of conservative substitutions, consensus sequence substitutions, germline substitutions, backmutations, and the like, is often referred to as "optimization" of a humanized antibody or chain. The phrase "substantially from a non-human immunoglobulin or antibody" or "substantially non-human" means having an immunoglobulin or antibody sequence at least <NUM>-<NUM>%, preferably <NUM>-<NUM>%, more preferably, <NUM>%, <NUM>%, <NUM>%, or <NUM>% identical to that of a non-human organism, e.g., a non-human mammal.

Accordingly, all regions or residues of a humanized immunoglobulin or antibody, or of a humanized immunoglobulin or antibody chain, except possibly the CDRs, are substantially identical to the corresponding regions or residues of one or more native human immunoglobulin sequences. The term "corresponding region" or "corresponding residue" refers to a region or residue on a second amino acid or nucleotide sequence which occupies the same (i.e., equivalent) position as a region or residue on a first amino acid or nucleotide sequence, when the first and second sequences are optimally aligned for comparison purposes.

The phrases "risk reduction" and "risk of" refer to the relative risk unless specified to mean absolute risk.

Patients amenable to treatment can be identified by determining the Mayo Stage of the patient's AL amyloidosis. Alternatively, or in addition, patients likely to receive a health benefit from the treatment can be identified by determining the 6MWD of the patient and determining the ejection fraction of the patient. Patients likely to respond positively to treatment are those with Stage IV AL amyloidosis, patients with a 6MWD of ≥ <NUM> meters and an EF of > <NUM>% at baseline, patients with Mayo Stage IV AL amyloidosis with an EF of > <NUM>% at baseline, and Mayo Stage IV patients with a 6MWD of ≥ <NUM> meters and an EF of > <NUM>% at baseline.

Provided herein are methods of treating a human patient showing symptoms of or diagnosed with Mayo Stage IV AL amyloidosis and/or a human patient having a baseline 6MWD of ≥ <NUM> meters and a baseline EF of ><NUM>%, comprising administering to the patient a regimen of any of the antibodies or antibody formulations described herein effective to improve the health status of the patient. Some of the patients have Mayo Stage IV AL amyloidosis and a human patient having a baseline 6MWD of ≥ <NUM> meters and a baseline EF of > <NUM>%. Some patients have Mayo Stage IV AL amyloidosis and a baseline EF of > <NUM>%. Some patients have systemic organ dysfunction attributed to AL amyloidosis, including dysfunction of the heart, kidney, liver, peripheral nervous system, gastrointestinal system, autonomic nervous system, lung, and/or soft tissue or lymphatic system.

Some methods involve determining the baseline level of troponin-T, NT-proBNP and relative levels of involved and uninvolved light chain in a patient, selecting the patient for treatment if the patient has a baseline level of cTnT ≥ <NUM> ng/mL or > <NUM> ng/mL, NT-ProBNP ≥ <NUM>,<NUM> pg/mL (and < <NUM> pg/mL) and FLC-diff ≥ <NUM>/dL, and administering an effective dosage of any of the antibodies disclosed herein. Some methods involve determining the 6MWD and EF of a patient at baseline and selecting the patient for treatment if the patient has a 6MWD of ≥ <NUM> meters and an EF of > <NUM>%. In some instances, Mayo Stage IV patients with baseline 6MWD of ≥ <NUM> meters and baseline EF of > <NUM>% are selected for treatment. Some methods involve determining the Mayo Stage and EF of the patient and in some instances Mayo Stage IV patients with a baseline EF of > <NUM>% are selected for treatment.

In some disclosures, the patient is treatment naive, meaning that the patient has not previously received any treatment for AL amyloidosis. Patients amenable to treatment also include those patients who have received, are currently receiving, or will later receive an alternate therapy for treatment of AL amyloidosis or an associated condition, such as, inflammatory diseases, chronic microbial infections, malignant neoplasms, inherited inflammatory diseases, and lymphoproliferative disorders. For example, patients may also receive or have received one or more of the therapeutic agents identified herein with respect to combination therapies. As an example, patients suffering from AL amyloidosis may also receive or have received or may later receive bortezomib, melphalan, lenalidomide, prednisone, dexamethasone, cyclophosphamide, pomalidomide, carfilzomib, doxorubicin, doxycycline, daratumumab, autologous transplant or combinations thereof. For those patients who have previously received alternate therapies for the treatment of amyloid disease, such therapies may or may not have been successful by the relevant clinical measures, and likely did not improve health status. Additional examples of such therapies include (<NUM>) CyBorD, which is a combination therapy comprising cyclophosphamide, bortezomib and dexamethasone, (<NUM>) BMDex, which is a combination of bortezomib, melphalan and dexamethasone, (<NUM>) MDex, which is a combination of melphalan and dexamethasone, (<NUM>) LDex, which is a combination of lenalidomide and dexamethasone, (<NUM>) CLD, which is a combination of cyclophosphamide, lenalidomide and dexamethasone, (<NUM>) PomDex, which is a combination of pomalidomide and dexamethasone, and (<NUM>) CRd, which is a combination of lenalidomide, cyclophosphamide and dexamethasone. Such patients may, or may not, have experienced cardiac and/or renal improvement as a result of such treatment.

An improvement in health status can be established when the patient exhibits an improvement in the six minute walk distance (meters) outcome measure (6MWD).

An improvement in the <NUM>-Item Short Form Survey Physical Component Score (SF-<NUM> PCS) or Short Form <NUM> questionnaire (SF-36v2) can also indicate an improvement in health status of the patient. For example, a patient treated with an antibody for at least nine months who scores at least <NUM> points higher on the SF-<NUM> PCS or SF-36v2 questionnaire than a different patient at the same time point who has not received the antibody has achieved an improvement in health status. In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's PCS, as measured by SF-<NUM> or SF36v2, of at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, at least <NUM>, or at least <NUM>. In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's PCS, as measured by SF-<NUM> or SF36v2, of about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, about <NUM>, or about <NUM>.

Reduced length of hospitalization stays or reduced frequency of hospitalization for more than <NUM> days of patients treated with the antibodies disclosed herein compared to patients who have not received antibody can also indicate an improvement in health status of the patient. Improvement in health status can also be shown by longer survival of the antibody treated patient compared to untreated patients around the same time. In some disclosures, treatment with an antibody disclosed herein can reduce the risk of all-cause mortality for the treated patient by at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, or at least <NUM>% relative to control treated patients, as can be determined by calculating hazard ratios between the treated patient and untreated patients.

In some disclosures, treatment with the antibodies disclosed herein can reduce the risk of all-cause mortality for the treated patient by about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, or about <NUM>% relative to control treated patients, as can be determined by calculating hazard ratios between the treated patient and untreated patients. In some disclosures, treatment with the antibodies disclosed herein can reduce the risk of all-cause mortality for the treated patient by about <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>% or <NUM>% relative to control treated patients, as can be determined by calculating hazard ratios between the treated patient and untreated patients.

For example, the risk of all-cause mortality for some Mayo Stage IV patients can be reduced by about <NUM>%, and by about <NUM>% for some Mayo Stage IV patients if such patients have some level of functional reserve prior to treatment as defined by baseline 6MWD of ≥ <NUM> meters and an ejection fraction of > <NUM>%.

In some disclosures, the risk of all-cause mortality for some Mayo Stage IV patients can be reduced by at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, or at least <NUM>% if they have an ejection fraction of > <NUM>%. In some disclosures, the risk of all-cause mortality for some Mayo Stage IV patients can be reduced by about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, or about <NUM>%if they have an ejection fraction of > <NUM>%. In some disclosures, the risk of all-cause mortality for some Mayo Stage IV patients can be reduced by about <NUM>% if they have an ejection fraction of > <NUM>%.

In some disclosures, the risk of all-cause mortality some patients having a baseline 6MWD of ≥ <NUM> meters and an ejection fraction of > <NUM>%, regardless of Mayo Stage, can be reduced by at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, or at least <NUM>% if they have an ejection fraction of > <NUM>%. In some disclosures, the risk of all-cause mortality some patients having a baseline 6MWD of ≥ <NUM> meters and an ejection fraction of > <NUM>%, regardless of Mayo Stage, can be reduced by about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, or about <NUM>%if they have an ejection fraction of > <NUM>%. In some disclosures, the risk of all-cause mortality in some patients having a baseline 6MWD of ≥ <NUM> meters and an ejection fraction of > <NUM>%, regardless of Mayo Stage, can be reduced by about <NUM>%. The risk of cardiac mortality for some Mayo Stage IV patients can be reduced by about <NUM>%.

In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's 6MWD by at least <NUM> meter, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, at least <NUM> meters, or at least <NUM> meters. In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's 6MWD by about <NUM> meter, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, about <NUM> meters, or about <NUM> meters.

In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's 6MWD by at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, at least <NUM>%, or at least <NUM>%. In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's 6MWD by about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, about <NUM>%, or about <NUM>%.

In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's survival by at least <NUM> month, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, or at least <NUM> months. In some disclosures, treatment with an antibody disclosed herein results in an increase of a patient's survival by about <NUM> month, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months, about <NUM> months.

In some disclosures, treatment is stopped for a patient with one or more of the following:.

Suitable antibodies, formulations and treatment regimens for the methods and uses disclosed herein are discussed in greater detail below.

The methods of the disclosure include administering to a patient an antibody that specifically bind to immunoglobulin light chain. Examples include antibodies that compete with <NUM>-1F4 for binding to immunoglobulin light chain, and antibodies that compete with 2A4 or 7D8 for binding to human amyloid A peptide, or specifically bind to the same epitope as <NUM>-1F4 (<CIT>), 2A4 or 7D8 (<CIT>). In some disclosures, the antibody is a humanized version of 2A4. In some disclosures, the antibody is a chimeric or humanized version of <NUM>-1F4, such as, for example, Ch mAb <NUM>-1F4, CAEL-<NUM>. In some disclosures, the antibody is one that is disclosed in <CIT>, <CIT>, and <CIT>. In some disclosures, the antibody comprises a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: <NUM>, <NUM> and <NUM>. In some disclosures, the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM>. In some disclosures, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: <NUM>.

In other methods, the antibody comprises light chain and heavy chain variable regions of a murine, chimeric, or humanized 2A4 antibody, or of a murine, chimeric, or humanized 7D8 antibody, as described in <CIT> and <CIT>, and the light chain and heavy chain variable region sequences described in the referenced patent and publication. Some formulations for the methods disclosed herein are described in <CIT> and <CIT>.

In some disclosures, the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM> and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: <NUM>-<NUM>. For example, the antibody can comprise a light chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM> and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM>. The antibody can include, or not include, the leader sequences of the above-noted light chain and heavy chain amino acid sequences. In some disclosures, the antibody is birtamimab (<NPL>).

In other methods, the antibody is a fragment of a 2A4 or 7D8 antibody, including chimeric and humanized versions thereof, such as a Fab fragment, a Fab' fragment, a F(ab')<NUM> fragment, F(ab)c, Dab, nanobody or Fv. As discussed in greater detail below, the antibody can be administered as a pharmaceutical formulation.

In some disclosures disclosed herein, the antibody can be administered to a patient as a pharmaceutical formulation, for example, comprising in addition to the antibody, a histidine buffer, trehalose, and polysorbate <NUM>. In some such formulations used in the methods described above, the antibody is present at a concentration within the range from about <NUM>/mL to about <NUM>/mL; the histidine buffer is present at a concentration within the range from about <NUM> to about <NUM>; the trehalose is present at a concentration within the range from about <NUM> to about <NUM>; the polysorbate <NUM> present at a concentration within the range from about <NUM>% to about <NUM>% by weight; and the pH is within the range from about <NUM> to about <NUM>. Some suitable formulations for the methods disclosed herein are described in greater detail below.

In some formulations, the antibody is present at a concentration within the range from about <NUM>/mL to about <NUM>/mL. In some formulations, the antibody is present at a concentration within the range from about <NUM>/mL to about <NUM>/mL. In some formulations, the antibody is present at a concentration within the range from about <NUM>/mL to about <NUM>/mL. For example, the antibody may be present at a concentration of about <NUM>/mL, or present at a concentration of about <NUM>/mL. The antibody may be present in a sterile liquid dosage form of about <NUM>/vial to about <NUM>/vial, or greater. For example, the antibody may be present in a sterile liquid dosage form of about <NUM>/vial. In another, non-limiting example, the antibody may be present as a sterile, lyophilized dosage form that may be reconstituted with sterile liquid dosage form of about <NUM>/vial. In another, non-limiting example, the antibody may be present as a sterile, lyophilized dosage form that may be reconstituted with sterile liquid of about <NUM> for a dosage form of about <NUM>/mL or about <NUM>/vial.

Antibodies used in the disclosed formulations can be coupled with a therapeutic moiety, such as a cytotoxic agent, a radiotherapeutic agent, an immunomodulator, a second antibody (e.g., to form an antibody heteroconjugate), or any other biologically active agent that facilitates or enhances the activity of a chimeric or humanized 2A4 or a chimeric or humanized 7D8 antibody. Representative therapeutic moieties include agent known to be useful for treatment, management, or amelioration of amyloid disease or symptoms of amyloid disease.

Therapeutic moieties and/or detectable substances may be coupled or conjugated directly to a murine, chimeric or humanized 2A4 antibody or a murine, chimeric or humanized 7D8 antibody, or indirectly, through an intermediate (e.g., a linker) using techniques known in the art. See e.g., <NPL>); <NPL>); <NPL>); "<NPL>), and <NPL>.

Antibodies used in the disclosed formulations also include modified forms of murine, chimeric or humanized 2A4 antibodies, or murine, chimeric or humanized 7D8 antibodies, which have increased in vivo half-lives relative to the corresponding unmodified antibodies. Such modified forms may be prepared, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. As one example, representative methods for antibody half-life extension are described in <CIT>.

The histidine buffer may be present in some formulations at a concentration of about <NUM>. In some formulations, the histidine buffer comprises L-histidine and L-histidine HCl monohydrate. For example, in some formulations, L-histidine is present at a concentration within the range from about <NUM> to about <NUM> and L-histidine HCl monohydrate is present at a concentration within the range from about <NUM> to about <NUM>.

In some formulations, trehalose is present at a concentration from about <NUM> to about <NUM>, for example, about <NUM>. In some formulations, a different non-reducing sugar is used, such as sucrose, mannitol, or sorbitol.

In some formulations, polysorbate <NUM> is present at a concentration within the range of about from about <NUM>% to about <NUM>% by weight, for example, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, <NUM>%, or <NUM>%. Alternatively, in some formulations, polysorbate <NUM> is present at a concentration within the range of about from about <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, <NUM>/L, or <NUM>/L. Some formulations include polysorbate <NUM> at a concentration of <NUM>/L.

Some formulations are characterized by a pH within the range of about <NUM>-<NUM>, for example, a pH of <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, or <NUM>. Some formulations have a pH of about <NUM>. Some formulations are characterized by an osmolality of about <NUM> mOsm/kg. A bulking agent may also be included some formulations.

Typically, the formulations are sterile, for example, as accomplished by sterile filtration using a <NUM> or a <NUM> filter. The formulations disclosed herein are also generally stable upon freezing and thawing.

Optionally, formulations disclosed herein may further comprise other excipients, such as saccharides, polyols, and amino acids (e.g., arginine, lysine, and methionine).

The present disclosure also provides formulations substantially free of surfactant, inorganic salts, additional sugars, and/or other excipients, i.e., less than about less than <NUM>%, less than <NUM>%, or less than <NUM>% of such compounds.

An exemplary formulation comprises an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM> and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: <NUM>, <NUM>, or <NUM>, which is present at a concentration of about <NUM>/mL, a histidine buffer present at a concentration of about <NUM>, trehalose present at a concentration of about <NUM>, polysorbate <NUM> present at a concentration of about <NUM>/L, and a pH of about <NUM>. Some formulations comprise an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM> and a heavy chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM>, which is present at a concentration of about <NUM>/mL, a histidine buffer present at a concentration of about <NUM>, trehalose present at a concentration of about <NUM>, polysorbate <NUM> present at a concentration of about <NUM>/L, and a pH of about <NUM>. Some formulations comprise birtamimab, which is present at a concentration of about <NUM>/mL, a histidine buffer present at a concentration of about <NUM>, trehalose present at a concentration of about <NUM>, polysorbate <NUM> present at a concentration of about <NUM>/L, and a pH of about <NUM>.

The methods disclosed herein involve pharmaceutical products comprising lyophilized antibody drug substance and instructions for reconstitution and use. For example, a representative pharmaceutical product can comprise: (a) a vial comprising about <NUM> antibody in powder form; (b) instructions for reconstitution of the antibody; and (c) instructions for preparing the reconstituted antibody for infusion, wherein (i) the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO: <NUM> and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs: <NUM>-<NUM>; and (ii) the reconstitution instructions require reconstitution with water for injection to an extractable volume of <NUM>.

As used herein, the terms "treat" and "treatment" refer to the alleviation or amelioration of one or more symptoms or effects associated with the disease, prevention, inhibition or delay of the onset of one or more symptoms or effects of the disease, lessening of the severity or frequency of one or more symptoms or effects of the disease, and/or increasing or trending toward desired outcomes as described herein.

Desired outcomes of the treatments disclosed herein vary according to the amyloid disease and patient profile and are readily determinable to those skilled in the art. Desired outcomes include an improvement in the patient's health status. Generally, desired outcomes include measurable indices such as reduction or clearance of pathologic amyloid fibrils, decreased or inhibited amyloid aggregation and/or deposition of amyloid fibrils, and increased immune response to pathologic and/or aggregated amyloid fibrils. Desired outcomes also include amelioration of amyloid disease-specific symptoms. For example, desired outcomes for the treatment of AL amyloidosis include a decrease in the incidence or severity of known symptoms, including organ dysfunction, peripheral and autonomic neuropathy, carpal tunnel syndrome, macroglossia, restrictive cardiomyopathy, arthropathy of large joints, immune dyscrasias, myelomas, as well as occult dyscrasias.

For example, the <NUM>-minute walk test (6MWT) can be a surrogate endpoint used to assess cardiac functional response (<NPL>). It measures the distance patients can walk in <NUM> minutes along thirty meter long hallways. For example, the mean <NUM>-minute walk distance (6MWD) of AL amyloidosis patients with cardiac involvement has been shown to be significantly shorter than the distance walked by AL amyloidosis patients without cardiac involvement. Further, increased distance walked is correlated with a decrease in mortality. A positive change in health-related quality of life is also a desired outcome of the disclosed therapies, including, for example, as measured by the SF-<NUM> Health Survey (<NPL>). The SF-<NUM> involves scores that represent eight dimensions of function and well-being: physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and mental health, and summary scores, such as physical component summary (PCS) and mental component summary (MCS). Higher SF-<NUM> scores represent better health. Desired outcomes of the disclosed therapies are generally quantifiable measures as compared to a control or baseline measurement. As used herein, relative terms such as "improve," "increase," or "reduce" indicate values relative to a control, such as a measurement in the same individual prior to initiation of treatment described herein, or a measurement in a control individual or group. A control individual is an individual afflicted with the same amyloid disease as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual are comparable), but who has not received treatment using the disclosed antibody formulations. In this case, efficacy of the disclosed antibody formulations is assessed by a shift or trend away from measurable indices in the untreated control. Alternatively, a control individual is a healthy individual, who is about the same age as the individual being treated. In this case, efficacy of the disclosed antibody formulations is assessed by a shift or trend toward from measurable indices in the healthy control. Changes or improvements in response to therapy are generally statistically significant and described by a p-value less than or equal to <NUM>, less than <NUM>, less than <NUM>, less than <NUM>, or less than <NUM> may be regarded as significant.

Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody, or employing radiolabeled SAP Scintigraphy over time. If the response falls, a booster dosage may be indicated. Changes in the health status of the patients can be monitored based on outcome measures such as 6MWD, SF-<NUM> PCS (SF-36v2), hospitalizations and survival as discussed in greater detail above. In addition, the response of patients with AL amyloidosis to treatment can be monitored by assessing cardiac markers, such as NT-proBNP and/or troponin-T, serum creatine, and/or alkaline phosphatase; by performing serum free light chain (SFLC) assays, quantitative immunoglobulin assays, biopsies, serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), serum, urine immunofixation electrophoresis (IFE), and/or organ imaging techniques. An exemplary complete response (CR) can be determined from response criteria including negative IFE of serum and urine, normal κ/λ ration and/or <<NUM> % plasma cells in bone marrow. An exemplary very good partial response (VGPR) can be determined from a dFLC of < <NUM>/L. An exemplary partial response (PR) can be determined from a dFLC decrease of ≥ <NUM>%. In the kidney, a response to treatment can be determined, for example, from a ≥ <NUM>% reduction (e.g., > <NUM>/<NUM> hours) in <NUM> hour urine protein excretion in the absence of either a reduction in eGFR of ≥ <NUM>% or an increase in serum creatine of ≥ <NUM>/dL. In the liver, a response to treatment can be determined, for example, from a ≥ <NUM>% reduction in initially elevated alkaline phosphatase or a ≥ <NUM> reduction in liver size on CT scan or MRI. In the heart, a response to treatment can be determined, for example, from a ><NUM>% and > <NUM> ng/L reduction in NT-proBNP in patients with baseline of NT-proBNP of > <NUM> ng/L. In the kidney, a response to treatment can be determined, for example, from a > <NUM>% decrease in proteinuria or a decrease in proteinuria to < <NUM>/<NUM> hours in the absence of renal progression. Neuropathy responders are generally characterized by < <NUM> point increase in NIS-LL from baseline. Improvement in neuropathy (e.g., improved nerve function) is determined from a decrease in the NIS-LL from baseline. Improvement in health status can also be determined from a decrease in the frequency of hospitalizations, a decrease in hospitalizations of greater than ninety days, or from longer survival relative to an untreated different patient with a similar prognosis upon diagnosis, for example, AL amyloidosis patients with cardiac involvement.

The antibody formulation can be administered intravenously or subcutaneously in dosage ranges from about <NUM>/kg to about <NUM>/kg of the host body weight. For example, dosages can be about <NUM>/kg body weight, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, about <NUM>/kg, or about <NUM>/kg body weight. The dosages can also be administered according to body surface area from about <NUM>/m2 to about <NUM>/m2, for example, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM>/m2. For intravenous dosing, an amount of the antibody formulation sufficient to achieve the desired dosage for the individual patient is transferred from one or more vials to one or more intravenous bags containing a liquid (e.g., saline) and administered to the patient.

Antibody is usually administered on multiple occasions. An exemplary treatment regimen entails administration once per every two weeks, once a month, or once every <NUM> to <NUM> months. For example, patients can receive the antibody formulation once every four weeks as a cycle, for example every twenty-eight days. The dosing frequency can be adjusted depending on the pharmacokinetic profile of the antibody formulation in the patient. For example, the half-life of the antibody may warrant a two week frequency of dosing. In some disclosures, the pharmaceutical formulation is administered intravenously every <NUM> days with an antibody dosage of about <NUM>/kg. For example, some patients may receive an intravenous dose of about <NUM>/kg birtamimab every <NUM> days. For example, some patients may receive an intravenous dose of about <NUM>/kg birtamimab every <NUM> days (±<NUM> days). In certain disclosures, a minimum of <NUM> days is required between doses. For some such patients, the birtamimab formulation transferred to the intravenous bag was first reconstituted from a lyophilized formulation to a formulation having a pH of about <NUM> and comprising about <NUM>/ml birtamimab, about <NUM> histidine buffer, about <NUM> trehalose and about <NUM>/L polysorbate <NUM>. For some patients the desired dosage can be administered subcutaneously without dilution from a vial containing any of the formulations disclosed herein.

In some disclosures disclosed herein, the antibody is administered to the patient for at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, at least <NUM> months, or for a longer period of time. For example, the pharmaceutical formulation is administered to the patient for a duration effective to achieve or maintain an improvement in health status as indicated by an increase in 6MWD or SF-<NUM> PCS score, or long enough to achieve or maintain a lower risk of mortality relative to an untreated patient. For some patients, the lower risk can be established after at least <NUM> months of treatment. For some patients, the lower risk can be established after at least <NUM> months of treatment. For some patients, the lower risk can be established after at least <NUM> months of treatment or after at least <NUM> months of treatment or after twenty-four months of treatment. For these patients, a lower risk of mortality correlates with longer survival times relative to untreated patients.

Also disclosed herein are combination therapies for treatment or prophylaxis of AL amyloidosis. Such combination therapies are performed by administering an antibody formulation disclosed herein in conjunction with one or more second therapeutic agents, such as another therapy to treat or effect prophylaxis of AL amyloidosis. Combination therapies as disclosed herein may also be performed in conjunction with a second therapy is used to treat or effect prophylaxis of a disease or condition associated with amyloid disease, such as an inflammatory disease, a chronic microbial infection, a neoplasm (including malignant neoplasms), an inherited inflammatory disease, and/or a lymphoproliferative disorder. Numerous treatments are available in commercial use, in clinical evaluation, and in pre-clinical development, any of which could be selected for use in combination with the disclosed antibody formulations. Such treatments can be one or more compounds or treatments selected from, but not limited to several major categories, namely, (i) non-steroidal anti-inflammatory drugs (NSAIDs; e.g., detoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenameate, mefenamic acid, meloxicam, nabumeone, naproxen sodium, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, rofecoxib, aspirin, choline salicylate, salsalte, and sodium and magnesium salicylate); (ii) steroids (e.g., cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone); (iii) DMARDs, i.e., disease modifying antirheumatic drugs (e.g., cyclosporine, azathioprine, methotrexate, leflunomide, cyclophosphamide, hydroxychloroquine, sulfasalazine, D-penicillamine, minocycline, and gold); (iv) recombinant proteins (e.g., ENBREL® (etanercept, a soluble TNF receptor) and REMICADE® (infliximab) a chimeric monoclonal anti-TNF antibody); (v) stem cell transplantation; and/or (vi) chemotherapy. Patients with AL amyloidosis may also receive treatment regimens that include drugs or combinations of drugs often used to treat hematological malignancies, such as melphalan, prednisone, dexamethasone, lenalidomide (REVLIMID®), proteosome inhibitors such as bortezomib (VELCADE®) and carfilzomib (KYPROLIS®), and CD38 agents such as daratumumab (DARZALEX®), at dosages in the range of the standard of care.

When performing a combination therapy, the two or more drug substances are administered simultaneously or sequentially in any order, i.e., a formulation disclosed herein is administered prior to administering a second drug substance, concurrently with a second drug substance, or subsequent to administration of a second drug substance. For example, a combination therapy may be performed by administering a first therapy prior to (e.g., <NUM> minute, <NUM> minutes, <NUM> minutes, <NUM> minutes, <NUM> minutes, <NUM> hour, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> week, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, or <NUM> weeks before), concomitantly with, or subsequent to (e.g., <NUM> minute, <NUM> minutes, <NUM> minutes, <NUM> minutes, <NUM> minutes, <NUM> hour, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> week, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, <NUM> weeks, or <NUM> weeks after) administering a second agent/therapy.

The dosage, frequency and mode of administration of each component of the combination can be controlled independently. For example, one therapeutic agent/therapy may be administered orally three times per day, while the second therapeutic agent/therapy may be administered intramuscularly once per day. Combination therapy may be given in on-and-off cycles that include rest periods. The compounds may also be admixed or otherwise formulated together such that one administration delivers both compounds. In this case, each therapeutic agent is generally present in an amount of <NUM>-<NUM>% by weight of the total weight of the composition. Alternatively, an antibody formulation disclosed herein and a second therapeutic agent can be formulated separately and in individual dosage amounts. Drug combinations for treatment can be provided as components of a pharmaceutical pack.

Preferably, the disclosed combination therapies elicit a synergistic therapeutic effect, i.e., an effect greater than the sum of their individual effects or therapeutic outcomes. Measurable therapeutic outcomes are described herein. For example, a synergistic therapeutic effect may be an effect of at least about two-fold greater than sum of the therapeutic effects elicited by the single agents of a given combination, or at least about five-fold greater, or at least about ten-fold greater, or at least about twenty-fold greater, or at least about fifty-fold greater, or at least about one hundred-fold greater. A synergistic therapeutic effect may also be observed as an increase in therapeutic effect of at least <NUM>% compared to the sum of the therapeutic effects elicited by the single agents of a given combination, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or at least <NUM>%, or more. A synergistic effect is also an effect that permits reduced dosing of therapeutic agents when they are used in combination.

Some methods of the disclosure include treating a subject having AL amyloidosis by determining one or more of the following prognostic indicators: (<NUM>) the Mayo Stage of the patient's AL amyloidosis, (<NUM>) the <NUM> minute walk distance (6MWD) and ejection fraction (EF) of the patient, and/or the Mayo Stage and the EF of the patient. Once the prognostic indicator(s) has been determined, a patient is selected the patient for treatment if the patient meets one of the following treatment criteria: (<NUM>) has Mayo Stage IV AL amyloidosis; (<NUM>) has a 6MWD ≥ <NUM> meters and an EF > <NUM>% at baseline; (<NUM>) has Mayo Stage IV and EF > <NUM>% at baseline; or (<NUM>) has Mayo Stage IV, a 6MWD ≥ <NUM> meters and an EF > <NUM>% at baseline. Treatment includes dministering an effective dosage of an antibody disclosed herein.

In one method of the disclosure, a patient meeting or more of the prognostic indicators is treated with birtamimab (<NUM>/kg) supplied as a sterile, lyophilized dosage form in a <NUM>/<NUM> vial containing <NUM> birtamimab. Each vial may be reconstituted with <NUM> sterile water for injection (WFI) to a concentration of <NUM>/mL resulting in a buffered, isotonic, preservative-free solution. Birtamimab is administered once every <NUM> days as an initial <NUM> (±<NUM>)-minute IV infusion. If the subject tolerates the initial infusion, subsequent infusions may be administered over <NUM> (±<NUM>) minutes. Dose are administered at intervals of at least <NUM> days.

Patients may also be treated with concomitant standard of care chemotherapy, which may include, for example, bortezomib administered subcutaneously on a weekly basis.

The following examples have been included to illustrate modes disclosed herein. Certain aspects of the following examples are described in terms of techniques and procedures found or contemplated by the present co-inventors to work well in the practice disclosed herein.

A Phase 2b global, multi-center, randomized, double-blind, placebo-controlled clinical study of NEOD001 vs. placebo was conducted in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction (PRONTO Study). The study enrolled <NUM> patients. Patients were randomized on a <NUM>:<NUM> basis to receive <NUM>/kg of NEOD001 (n=<NUM>) or placebo (n=<NUM>) via intravenous infusion every <NUM> days. The primary outcome measure was cardiac best response as measured by NT-proBNP through <NUM> months of treatment. Secondary outcome measures included change in Short Form-<NUM> (SF-<NUM> Questionnaire, change in <NUM> minute walk test (6MWT), renal best response as measured by proteinuria, change in Neuropathy Impairment Score - Lower Limb (NIS-LL) score and NT-proBNP slope. Additional information regarding the clinical study design is available on https://clinicaltrials. The PRONTO Study did not meet its primary or secondary endpoints.

A Phase <NUM> global, multi-center, randomized, double-blind, placebo-controlled clinical study of NEOD001 vs. placebo was conducted in newly diagnosed, treatment-naive patients with AL amyloidosis and cardiac dysfunction, with both arms of the study receiving standard of care (VITAL Study; The VITAL Amyloidosis Study, a Global Phase <NUM>, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL), ClinicalTrials. gov Identifier: NCT02312206). The study enrolled <NUM> patients (see Table <NUM>).

Patients were randomized on a <NUM>:<NUM> basis to receive <NUM>/kg of NEOD001 or placebo via intravenous infusion every <NUM> days. All patients received bortezomib based chemotherapy concurrently with NEOD001 or placebo. Placebo was administered as a <NUM> bag of normal saline once every <NUM> days. The primary outcome measures were time to composite of all-cause mortality or cardiac hospitalization. Secondary outcome measures included NT-proBNP best response, time to cardiac mortality or cardiac hospitalization, change in the <NUM> minute walk test, change in the Short Form-<NUM> questionnaire, change in the Kansas City Cardiomyopathy questionnaire, renal best response as assessed using Palladini et al, <NUM> criteria and hepatic best response as assessed using Comenzo et al, <NUM> criteria. Additional information regarding the clinical study design is available on https://clinicaltrials. Based on the results from the PRONTO Study, a futility analysis was performed on the ongoing VITAL Study. The futility analysis, based on <NUM> adjudicated events of the <NUM> events specified to complete the study, was not statistically significant. The hazard ratio (HR) was <NUM> favoring NEOD001 vs. control arm (HR, <NUM>, <NUM>% confidence interval [CI], <NUM>-<NUM>; P=<NUM>). Based on the results from the PRONTO Study and the futility analysis of the VITAL Study, clinical development of NEOD001 was discontinued.

Following the discontinuation of NEOD001 development, statistical analysis analysis was performed on the VITAL Study data, which necessarily includes censored data due to the study termination. The data was censored at twelve months. The final study results were consistent with the futility analysis. NEOD001 was not significantly different from control for the primary endpoint of all-cause mortality or cardiac hospitalization (≥ <NUM> days) (HR, <NUM>; <NUM>% CI <NUM>-<NUM>; P=<NUM>; see Table <NUM>; and <FIG>). Nor was NEOD001 significantly different from control for any key secondary endpoints (SF-<NUM> PCS, 6MWD, NT-proBNP best response, or renal best response). Subsequent post hoc analyses for subjects categorized as Mayo Stage IV yielded an even stronger result favoring birtamimab (HR=<NUM>), revealing a potential survival benefit for this subset of patients.

Surprisingly, analysis of the data suggested an improvement in health status in certain subsets of patients, namely Mayo Stage IV patients (n=<NUM> of <NUM>; approximately <NUM>% of the patients enrolled in the VITAL study were Mayo stage IV) and patients having a baseline 6MWD of greater than <NUM> meters and an ejection fraction of greater than <NUM>% regardless of Mayo stage (n=<NUM>). The hazard ratios for such patient subpopulations were <NUM> and <NUM>, respectively, in favor of treatment, as the median overall survival in stage IV (mITT) was <NUM> months in the placebo + SOC group and was not reached (><NUM> months) in the NEOD001 + SOC group (see <FIG>). Further, the observed benefit appears to be further enhanced for Mayo Stage IV patients with baseline 6MWD of ≥<NUM> meters and an ejection fraction (EF) of > <NUM>% (n=<NUM>). The hazard ratio for such patients was <NUM> in favor of treatment. In addition, a benefit was also observed in Mayo Stage IV patients with an ejection fraction (EF) of > <NUM>% (n=<NUM>), without regard to 6MWD. It is surprising that greater improvement was observed in Mayo Stage IV patients than in Stage I-III patients because it is generally accepted that treatment intervention at earlier stages of diseases associated with amyloid burden is required to achieve an improvement.

As shown in <FIG>, Mayo Stage IV patients treated with NEOD001 demonstrated a greater improvement in health status, as measured by the composite of all-cause mortality or cardiac hospitalization for more than <NUM> days through <NUM> months, relative to patients treated with placebo, compared to the difference seen with Stage I-III patients, with Stage IV patient results having an HR of <NUM> (<NUM>% relative risk reduction) with p=<NUM> (<FIG>) as compared to. <NUM> (<NUM>% relative risk reduction) with p=<NUM> for Stage I-III patients (<FIG>).

As shown in <FIG>, Stage IV patients treated with NEOD001 demonstrated a greater improvement in health status, as measured by all-cause mortality through <NUM> months, relative to patients treated with placebo, compared to the difference seen with Stage I-III patients, with Stage IV patient results having an HR of <NUM> (<NUM>% relative risk reduction) with p=<NUM> (<FIG>) as compared to <NUM> (-<NUM>% relative risk reduction) with p=<NUM> for Stage I-III patients (<FIG>).

As shown in <FIG>, Stage IV patients treated with NEOD001 demonstrated a greater improvement in health status, as measured by cardiac mortality through <NUM> months relative to patients treated with placebo, compared to the difference seen with Stage I-III patients, with Stage IV patient results having an HR of <NUM> (<NUM>% relative risk reduction) with p=<NUM> (<FIG>) as compared to <NUM> (-<NUM>% relative risk reduction) with p=<NUM> for Stage I-III patients (<FIG>).

As shown in Table <NUM>, Stage IV patients treated with NEOD001 demonstrated a greater improvement in health status, as measured by SF-<NUM> PCS score change from baseline to Month <NUM>, relative to patients treated with placebo, compared to the difference seen with Stage I-III patients, with Stage IV patient having a change of +<NUM> points with p=<NUM> as compared to a change of -<NUM> with p=<NUM> for Stage I-III patients. Abbreviations: LSM (Least Squares Mean); SE (Standard Error); CI (Confidence Interval). In the mITT analysis, SF-<NUM> PCS scores showed significantly less deterioration from baseline to <NUM> months (P<<NUM>) and <NUM> months (P<<NUM>) in the NEOD001 + SOC group compared with the placebo + SOC group (see <FIG>), and change from baseline in 6MWD was significantly greater at all time points through month <NUM> in the NEOD001 + SOC group versus the placebo + SOC group.

As shown in Table <NUM>, Stage IV patients treated with NEOD001 demonstrated a greater improvement in health status, as measured by 6MWD change in rank order from baseline to Month <NUM>, relative to patients treated with placebo, compared to the difference seen with Stage I-III patients, with Stage IV patient having a change in rank order of +<NUM> with p=<NUM> as compared to a change of -<NUM> with p=<NUM> for Stage I-III patients.

Change from baseline in 6MWD was significantly greater at all time points through month <NUM> in the NEOD001 + SOC group versus the placebo + SOC group. Mean (SD) duration of exposure was <NUM> (<NUM>) years in the NEOD001 + SOC group and <NUM> (<NUM>) years in the placebo + SOC group. The mean (SD) number of infusions received was <NUM> (<NUM>) and <NUM> (<NUM>) in the NEOD001 + SOC and placebo + SOC groups, respectively. Table <NUM> sets forth a summary of the VITAL Study results in Mayo Stage IV patients.

As shown in <FIG>, patients with a baseline six minute walk distance (6MWD) of greater or equal to <NUM> meters and an ejection fraction (EF) of greater than <NUM>% who were treated with NEOD001 demonstrated a greater improvement in health status, as measured by all-cause mortality through <NUM> months relative to patients treated with placebo. The results of patients of all Mayo stages having a baseline 6MWD ≥<NUM> meters and EF of > <NUM>% had an HR of <NUM> (<NUM>% relative risk reduction) with p=<NUM> and <NUM>% CI (<NUM>, <NUM>) (<FIG>). The results of Mayo Stage IV patients having a baseline 6MWD ≥<NUM> meters and EF of > <NUM>% had an HR of <NUM> (<NUM>% relative risk reduction) with p=. <NUM> and <NUM>% CI (<NUM>, <NUM>) <FIG>. In addition, Mayo Stage IV patients having a bseline EF of > <NUM>% had an HR of <NUM> (<NUM>% relative risk reduction) with p=<NUM> and <NUM>% CI (<NUM>, <NUM>).

Overall, <NUM> patients in the safety population experienced <NUM> or more treatment-emergent AEs (TEAEs; see Table <NUM>). The most common TEAEs (fatigue, nausea, peripheral edema, constipation, and diarrhea) were similar in both treatment arms, and both treatment arms had similar frequencies of serious TEAEs (NEOD001 + SOC, <NUM>%; placebo + SOC, <NUM>%). Of the <NUM> serious AEs reported by <NUM> NEOD001-treated patients, the majority (<NUM>%) were considered not related to study drug, and TEAEs leading to death occurred more frequently in the placebo + SOC group (<NUM> subjects, <NUM>%) than in the NEOD001 + SOC group (<NUM> subjects, <NUM>%). None of the deaths were considered to be related to study drug; cause of death in both groups was consistent with underlying disease and the known risk of cardiac complications. Overall safety results were similar within and across Mayo stages.

aSubjects reporting more than one adverse event are counted only once using the closest relationship to study drug, as assessed by the investigator. CTCAE, common terminology criteria for adverse events; SOC, standard of care; TEAE, treatment-emergent adverse event.

The primary objective of the study (NEOD001-<NUM>) is to evaluate the efficacy of birtamimab plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality. Secondary objectives are to evaluate birtamimab plus standard of care on the following: (<NUM>) change from baseline to month <NUM> in health related quality of life using the Short Form <NUM> questionnaire (SF-36v2), and (<NUM>) change from baseline to month <NUM> in the <NUM> Minute Walk Test (6MWT) distance (meters).

Newly diagnosed Mayo Stage IV subjects with AL amyloidosis receive birtamimab plus local standard of care chemotherapy. The initial first-line chemotherapy regimen must include bortezomib. Subjects remain on study until study completion, which occurs when approximately <NUM> primary endpoint events (all-cause mortality) have been reached or <NUM> subjects have completed <NUM> months of treatment. If the subject discontinues study drug prior to the end of the study, but is willing to continue to participate in study visits, the subject should have an Early Treatment Discontinuation (ETD) visit within <NUM>-<NUM> days after the last study drug administration and then have assessments every third month (see Table <NUM>). All visits after the ETD Visit should occur on schedule, that is, at the time when the visit would have occurred had the subject remained on study drug.

Subject screening will occur during the <NUM> days prior to the first administration of study drug on Month <NUM>-Day <NUM>. The screening period may be extended upon approval by the Medical Monitor. Screening assessments are listed in Table <NUM>, herein.

Two screening 6MWTs are required before the first administration of study drug. The first screening 6MWT is required to be performed between Days -<NUM> and <NUM>, at least <NUM> days prior to the second Screening 6MWT, which should be performed within <NUM> days prior to Month <NUM> Day <NUM>. The postbaseline 6MWTs may be performed on the same day as study drug administration and must be completed prior to study drug infusion. If all eligibility requirements are met, Month <NUM>-Day <NUM> assessments are completed, and treatment is initiated. Each visit is denoted by its "month" and "day" such that the first study drug infusion day is denoted as Month <NUM>-Day <NUM>; subsequent months use sequential numbers (e.g., the second dose is administered on Month <NUM>-Day <NUM>). "Cycle" is reserved to denote administration of chemotherapy. Assessment and visit windows are described in the Schedule of Events (Table <NUM>). Each month, subjects receive their study drug infusion on Day <NUM> at the study site. For Months <NUM> through <NUM>, subjects are assessed weekly, although not all visits are required to be at the study site. For Month <NUM> and all subsequent months until the end of the study, subjects are only required to return to the study site every <NUM> days for Day <NUM> dosing of study drug.

First-line chemotherapy must be a bortezomib-containing regimen, with bortezomib administered subcutaneously (SC), weekly. The first administration of chemotherapy, including bortezomib, is administered after Month <NUM> Day <NUM> study drug administration (following the post-study drug infusion observation period) such that Month <NUM>-Day <NUM> of the study is equivalent to Cycle <NUM> Day <NUM> of chemotherapy. In addition to the visits outlined above, during the first cycle of chemotherapy, the subject must return to the study site for each weekly administration of bortezomib and for assessments prior to the administrations. During the second and third cycles of chemotherapy, bortezomib must be administered at the study site during the Month <NUM>-Day <NUM>, Month <NUM>-Day <NUM>, and Month <NUM>-Day <NUM> visits (i.e., Cycle <NUM> Day <NUM>, Cycle <NUM>-Day <NUM>, and Cycle <NUM>-Day <NUM>, respectively). If, for any reason in the opinion of the Investigator, the subject should continue to be seen weekly at the study site (e.g., toxicity that appears to exceed the anticipated side effects of the chemotherapy), then the other Cycle <NUM> and Cycle <NUM> weekly bortezomib administrations may be performed at the study site, as well. At the Investigator's discretion, if the subject is not experiencing any unanticipated or significant toxicity, the subject may be administered the Cycle <NUM>-Days <NUM> and <NUM> and the Cycle <NUM> Days <NUM>, <NUM> and <NUM> bortezomib by their local physician, rather than by the Investigator. Within <NUM> day prior to or on the day of each administration of bortezomib by the local physician, a healthcare professional must obtain pre-dose vital signs and central laboratory samples. However, if bortezomib is administered on a Monday (or there is an intervening holiday), then it is acceptable for the Homecare visit to take place on the previous Friday.

In the event that bortezomib doses are missed, the chemotherapy cycles may become misaligned with the monthly study drug dosing. In this case, the weekly visits during Months <NUM> through <NUM> should continue as described above in order to closely monitor subjects' health during the initial months of concomitant chemotherapy. Throughout the study, monthly doses of study drug should not be delayed or skipped due to adjustments that are made to chemotherapy dosing.

Safety and efficacy assessments are performed at each visit.

Study Drug: Study drug consists of birtamimab (<NUM>/kg) supplied as a sterile, lyophilized dosage form in a <NUM>/<NUM> vial containing <NUM> birtamimab. Each vial is reconstituted with <NUM> sterile water for injection (WFI) to a concentration of <NUM>/mL resulting in a buffered, isotonic, preservative-free solution. Study drug is administered once every <NUM> days as an initial <NUM> (±<NUM>)-minute IV infusion. If the subject tolerates the initial infusion, subsequent infusions may be administered over <NUM> (±<NUM>) minutes. The length of the infusion may be extended over a longer period of time if and when it is clinically indicated. A minimum of <NUM> days between doses is required.

Premedication: All subjects are premedicated for each dose of study drug with <NUM> diphenhydramine (or an equivalent dose of a H1 antihistamine) and <NUM> acetaminophen (or an equivalent paracetamol dose) within <NUM>-<NUM> minutes prior to study drug administration.

Standard of Care Chemotherapy: All subjects receive concomitant standard of care chemotherapy, which must include bortezomib administered subcutaneously on a weekly basis for the initial, first-line chemotherapy regimen. Subsequent chemotherapy regimens may be prescribed as per standard of care at the Investigator's discretion. Antiviral prophylaxis is required.

Analysis Populations. The Intent-to-Treat (ITT) Population includes all subjects with Mayo Stage IV AL amyloidosis who receive any amount of study drug. The ITT Population is the primary population used for efficacy and safety analyses.

Efficacy Analyses. Primary Analysis - The primary endpoint is time to all-cause mortality. For all-cause mortality, all deaths occurring after the first infusion of study drug (Study Day <NUM>) through the study's last subject last visit (LSLV) are included. Using an exponential survival model, the estimated survival percentage at <NUM> months is estimated. Using an exact binomial test, the estimated survival percentage is compared to the historical control value of <NUM>%.

Key Secondary Efficacy Analyses - If the primary analysis concludes in favor of birtamimab, then the data for the placebo plus SOC Mayo Stage IV subjects from Study NEOD001 CL0002 [VITAL] is used to compare: (<NUM>) Change from baseline to Month <NUM> in the PCS score of the SF-36v2, and/or (<NUM>) Change from baseline to Month <NUM> in the 6MWT distance (meters). For both of these variables, change from baseline to Month <NUM> and <NUM>% confidence intervals are computed. If the lower bounds of the confidence intervals are greater than the observed values from the placebo group in VITAL, then the study concludes that that birtamimab is superior to control.

Claim 1:
An antibody comprising a heavy chain variable region comprising heavy chain CDRs of SEQ ID NO: <NUM>, <NUM>, and <NUM>, and a light chain variable region comprising light chain CDRs of SEQ ID NOs: <NUM>, <NUM>, and <NUM> for use in a method of treating AL amyloidosis in a patient, wherein the patient has been previously selected as having:
(a) Mayo Stage IV AL amyloidosis;
(b) a 6MWD of ≥ <NUM> meters at baseline and an EF of > <NUM>% at baseline;
(c) Mayo Stage IV AL amyloidosis and an EF of > <NUM>% at baseline; or
(d) Mayo Stage IV AL amyloidosis, a 6MWD of ≥ <NUM> meters at baseline, and an EF of > <NUM>% at baseline.